Diabetes Meeting Market Analysis and Reports | UK Conference Series

Market Analysis - Diabetes Meeting 2017

Importance & Scope

Healthcare for London has already identified that much needs to be done to improve the care of people with polygenic disease in London and to bring care up to the national standards to deliver the polygenic disease National Services Framework. The very fact that less than 15 august 1945 of Londoners with diabetes have undertaken structured patient education and a similar proportion are unaware of which type of polygenic disease they need is indicative of the very fact that London has not adequately invested with in polygenic disease care. Polygenic disease uk so welcomes the aid for London programme which we believe will improve prioritisation, investment and organisation of integrated polygenic disease care. Folks with polygenic disease want access to the right skills, within the right place, at the right time through Renaissance man, specialist and social care operating along. We have a tendency to be notably happy that the aid for London model recognises these desires and holds folks with polygenic disease at its heart, in terms of care coming up with and user involvement to deliver supported self-management. The aspirations of the set up are challenging however we have a tendency to believe they will be achieved and appearance forward to tributary to measurable enhancements over future 3 years. The case for ever-changing the means we have a tendency to deliver polygenic disease care within the capital is compelling. There are quite 2 million folks with polygenic disease within the UK1 and prevalence is expected to extend within the future. There are, moreover, vital inequalities within the means polygenic disease is prevented, diagnosed and treated across London. Folks with semi-permanent conditions are the most important users of aid in London and account for eightieth of general practitioner consultations nationally. Disbursal on polygenic disease currently accounts for associate degree calculable 100% of the NHS budget. Healthcare for London aims to dramatically improve access to high-quality polygenic disease take care of all Londoners and to scale back health inequalities within the capital. a brand new model of care and care pathways are developed with aid professionals, folks with polygenic disease and commissioners. It’ll place patients at the centre of care provision. Folks with polygenic disease are supported to self-manage their condition through education programmes, put together in agreement tending plans, and a lot of support and recommendation from trained professionals. A serious goal is to improve interference and early detection of polygenic disease. We have a tendency to also be seeking to forestall complications and supply applicable acute management for folks with polygenic disease. To achieve this we'd like to supply higher education for folks with polygenic disease and training for the hands, with a larger emphasis on self-management. We have a tendency to conjointly ought to higher manage polygenic disease in maternity, in children and adolescents with polygenic disease, and for folks receiving care in inmate settings

One in 10 people aged between 20 and 79 in England will die of diabetes related conditions. The impact of diabetes on mortality rates in London is significant:

• London has the highest percentage of deaths in England attributable to diabetes for people aged 20-79 years.

• London has higher than average deprivation which is a major risk factor for mortality from diabetes (figure 3).

• Two-thirds of these deaths are premature (aged under 75 years) and therefore represent a significant economic loss to society.

• Almost 12% of all premature deaths in London are attributable to diabetes. Life expectancy is reduced by 25% (five years for males and seven years for females) if diabetes develops at age 55 years, and more if it develops at a younger age.

Market Value on Diabetic Research:

The Type 2 Diabetes Mellitus (T1DM) market across the eight major countries of the US, Canada, France, Germany, Italy, Spain, the UK and Japan will expand from $4.2 billion in 2014 to $7.1 billion by 2021, at a robust Compound Annual Growth Rate (CAGR) of 7.9%, according to business intelligence provider GBI Research.

The type 2 diabetes treatment market in Asia-Pacific (APAC) will rise in value from an estimated $6.5 billion in 2013 to $10.5 billion by 2020, representing a modest Compound Annual Growth Rate (CAGR) of 7.1%, according to business intelligence provider GBI Research.

Over 29.1 million people (9.3 percent) of the U.S. population currently has diabetes, reports the Centers for Disease Control, and it is an epidemic that seems to be growing. Not only is diabetes detrimental to one’s health, but it is also a costly disease to treat. The total estimated cost of diagnosed diabetes in 2012 was $245 billion, according to the ADA, including $176 billion in direct medical costs and $69 billion in reduced productivity.

  

Europe: The number of people living with diabetes in Europe is expected to increase from 52 million in 2014 to 68.9 million by 2035, according to the International Diabetes Federation (IDF) . Across Europe, around 1 in 11 adults is affected and this number is set to rise as the population ages.

USA: Diabetes Mellitus has been growing at an exponential rate and World Health Organization (WHO) estimates that the diabetic population is likely to reach 366 million in 2030 . The United States is expected to have an increase of 102 per cent in the diabetic epidemic in 2030 when compared to 2000

Middle East: The rate of diabetes in parts of the Arabian Peninsula is over twice the global average rate, and much higher than some other areas of the Middle East and North Africa (MENA) . And cases of type-2 diabetes outnumber cases of type-1 diabetes by a ratio of 10:1.

Asia Pacific: The Asia-Pacific Diabetes Care Devices Market has been estimated at USD 2.461 Billion in 2015 and is projected to reach USD 3.518 billion by 2020,at a CAGR of 7.41% during the forecast period from 2015 to 2020.

 

 

Being recognized as a world-renowned organization, Conference Series LLC takes pride to introduce the commencement of “22nd International Congress on Prevention of Diabetes and Complications" from October 12-13, 2017 at London, UK. The conference aims to provide an opportunity to share knowledge, expertise along with unparalleled networking opportunities between a large number of medical and industrial professionals in this sphere. Conference series LLC’s Diabetes Meeting 2017 conference gathers renowned scientists, physicians, surgeons, young researchers, industrial delegates and talented student communities in the field of diabetic medicine under a single roof where networking and global partnering happens for the acceleration of future research.

Conference series LLC through its Open Access Initiative is committed to make genuine and reliable contributions to the scientific community. Conference series LLC hosts over 400 leading-edge peer reviewed Open Access journals and has organized over 300 scientific conferences all over the world.

Conference Series LLC welcomes all the scientists, physicians, surgeons, young researchers, industrial delegates and talented student communities in the field of diabetic medicine to attend this Diabetes Conferences, where all the aspects of diabetes will be discussed under single roof. Diabetes Meeting 2017 will be an excellent amalgamation of academia and industry as it involves every aspects of empirical and conceptual thinking in exploring new dimensions in this field.  It is open to all types of research methodologies both from academia and industry.

Diabetes Meeting 2017 is an international platform for presenting research about “Diabetes from monitoring to management” exchanging ideas about it and thus, contributes to the dissemination of knowledge in management of the disease for the benefit of the society. Diabetes Meeting 2017 is where the future of management and novel therapeutics for the disease intersects.